Brief: Tenaya Therapeutics Announces Updates On TN-201 Gene Therapy Program For MYBPC3-Associated HCM
17/10/2024 21:37
Oct 17 (Reuters) - Tenaya Therapeutics Inc TNYA.O :
* TENAYA THERAPEUTICS ANNOUNCES UPDATES ON TN-201 GENE
THERAPY
PROGRAM FOR MYBPC3-ASSOCIATED HCM
* TENAYA THERAPEUTICS INC - INITIAL DATA FROM COHORT 1 TO BE
REPORTED IN DECEMBER 2024
* TENAYA THERAPEUTICS : INDEPENDENT DATA SAFETY & MONITORING
BOARD
ENDORSED DOSE ESCALATION & BROADENING OF ELIGIBILITY CRITERIA;
COHORT 2 NOW ENROLLING
Source text for Eikon: ID:nGNXc2ZnXc
Further company coverage: TNYA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tenaya Therapeutics
See all newsTenaya Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Tenaya Therapeutics Q2 net loss widens on impairment charge
Brief: Tenaya Therapeutics Q2 Net Income USD -43.393 Million
Brief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401